TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia

Stock Information for TC BioPharm (Holdings) plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TC BioPharm (Holdings) plc

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
TCBP Adjourns General Meeting Until a Later Date
TCBP Announces Exercise of Series D Warrants For Cash
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"
/C O R R E C T I O N -- TC BioPharm/
TCBP Announces Shareholder Update Call on March 5th 2024
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.